Neumora Therapeutics, Inc. Common Stock Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

NMRA

Rank in Stocks #21554
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$0.3339
Last synced: 2026-11-20
Market Cap
$62.74M
Change (1 day)
-3.78%
Change (1 year)
-85.67%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Trade Neumora Therapeutics, Inc. Common Stock (NMRA)

Category

Healthcare
P/B ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)
P/B ratio as of November 2026 TTM: 1.78
According to Neumora Therapeutics, Inc. Common Stock's latest financial reports and stock price, its current price-to-book ratio (TTM) is 1.78. At the end of 2025 the company had a P/B ratio of 2.82.
P/B ratio history for Neumora Therapeutics, Inc. Common Stock from 2019 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 1.78 -36.74%
2025 2.82 -52.16%
2024 5.89 1.94%
2023 5.77 -204.48%
2022 -5.53 -27.22%
2021 -7.59 -70.98%
2020 -26.16 0.00%
2019 0.00 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.5305 266.08%
US
13.101 634.40%
US
4.451 149.51%
AU
4.8339 170.97%
BE
7.2161 304.51%
NL

Questions about Neumora Therapeutics, Inc. Common Stock's P/B ratio

What is Neumora Therapeutics, Inc. Common Stock's P/B ratio?

Neumora Therapeutics, Inc. Common Stock's P/B ratio is 1.78, as of Nov 2026.

What was Neumora Therapeutics, Inc. Common Stock's P/B ratio in 2025?

In 2025, Neumora Therapeutics, Inc. Common Stock's P/B ratio was 2.82, compared with 5.89 in 2024.

How has Neumora Therapeutics, Inc. Common Stock's P/B ratio changed since 2020?

From 2020 to 2025, Neumora Therapeutics, Inc. Common Stock's P/B ratio was highest in 2024 (5.89) and lowest in 2020 (-26.16).

How does Neumora Therapeutics, Inc. Common Stock's P/B ratio compare with similar companies?

Neumora Therapeutics, Inc. Common Stock's P/B ratio (1.78) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 13.10.